Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 2/20 | 0.74 |
| ▸ | GSK3A | P49840 | 1/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.67 |
| ▸ | TTR | P02766 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | IGF1R | P08069 | 3/20 | 0.63 |
| ▸ | PIM1 | P11309 | 2/20 | 0.61 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30990563 | 1.00 | NAT1 (0.74) | NAT1GSK3APTPN1TTRKMT2A | |
| SCHEMBL1249948 | 1.00 | NAT1 (0.74) | NAT1GSK3APTPN1TTRKMT2A | |
| SCHEMBL8180676 | 0.87 | GSK3A (0.79) | NAT1GSK3APTPN1TTRKMT2A | |
| SCHEMBL8180678 | 0.87 | GSK3A (0.79) | NAT1GSK3APTPN1TTRKMT2A | |
| SCHEMBL9570595 | 0.85 | MEN1 (0.74) | NAT1TTRKMT2AMEN1ALDH1A1 | |
| SCHEMBL8309671 | 0.85 | NAT1 (1.00) | NAT1PIM1GSK3BPDE4B | |
| SCHEMBL9570599 | 0.85 | MEN1 (0.74) | NAT1TTRKMT2AMEN1ALDH1A1 | |
| SCHEMBL8309670 | 0.85 | NAT1 (1.00) | NAT1PIM1GSK3BPDE4B | |
| SCHEMBL13846584 | 0.84 | PTP4A3 (0.60) | NAT1GSK3APTPN1TTRKMT2A | |
| SCHEMBL4089557 | 0.84 | PTP4A3 (0.60) | NAT1GSK3APTPN1TTRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1214305-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2001016123-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-8790855-B2 | Charge control agent and toner using same | HODOGAYA CHEMICAL CO., LTD (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8790855-B2 | Charge control agent and toner using same | HODOGAYA CHEMICAL CO., LTD (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2618218-A1 | CHARGE CONTROL AGENT AND TONER USING SAME | Hodogaya Chemical Co., Ltd. (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20130177843-A1 | CHARGE CONTROL AGENT AND TONER USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20130177843-A1 | CHARGE CONTROL AGENT AND TONER USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| WO-2006005683-A1 | PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
| EP-1610812-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| EP-1429763-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003027081-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | NAT1 4334/4885GSK3A 4713/4885PTPN1 2624/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | NAT1 4479/4885GSK3A 3934/4885PTPN1 2200/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | NAT1 4542/4885GSK3A 3226/4885PTPN1 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.